NAFLD patients are characterized by low levels of plasma endogenous secretory receptor for advanced glycation end products (esRAGE), interleukin (IL)-10, and adiponectin, and increased amounts of CD40 ligand, endogenous thrombin potential, and oxidized low-density lipoproteins (LDL) [24]. The gene discussed is CD40LG; the disease is metabolic dysfunction-associated steatotic liver disease.